Emergent BioSolutions' Ready to Rescue campaign promotes opioid overdose awareness and preparedness at U.S. colleges through partnerships and education.
Quiver AI Summary
Emergent BioSolutions has announced the return of its Ready to Rescue campaign, led by Zac Clark, Founder and CEO of Release Recovery, to U.S. college campuses in honor of International Overdose Awareness Day. Partnering with professional baseball player Davis Schneider, the campaign aims to raise awareness about opioid poisoning and promote the use of NARCAN® Nasal Spray to reverse overdoses. The initiative emphasizes the importance of preparedness and education around opioid emergencies, which continue to pose significant health risks globally, as evidenced by high rates of opioid-related deaths. Clark, sharing his personal experience with opioid dependency, encourages individuals to carry naloxone and be ready to act in crisis situations. Meanwhile, Schneider, who lost his brother to an overdose, reinforces the need for empathy and action in combating the opioid crisis, particularly in Canada, where opioid poisonings claim an average of 15 lives daily.
Potential Positives
- Emergent BioSolutions is reaffirming its commitment to fighting the opioid crisis, which reinforces its public health leadership and responsibility.
- The Ready to Rescue campaign will actively engage U.S. college campuses, targeting a younger audience with educational resources and potential future customers for NARCAN® Nasal Spray.
- The collaboration with public figures like Zac Clark and Davis Schneider enhances the campaign's visibility and credibility, leveraging personal stories to resonate with the public.
- The recent approval of NARCAN® Nasal Spray as an over-the-counter product positions Emergent as a key player in accessible opioid overdose intervention, potentially leading to increased product demand and sales.
Potential Negatives
- Emergent's partnership with individuals who have personal experiences with opioid dependency, such as Zac Clark, may raise concerns over the company’s public image, as it positions the campaign amid sensitive discussions about addiction recovery.
- The focus of the Ready to Rescue campaign on college campuses could be viewed as a reactive measure to ongoing public health crises rather than a proactive approach, potentially reflecting a lack of comprehensive long-term strategies from Emergent in addressing opioid addiction.
- The need for naloxone products like NARCAN® indicates a continuing crisis; the ongoing prevalence of opioid overdoses could suggest that previous initiatives by Emergent have not fully addressed the opiate epidemic effectively.
FAQ
What is the Ready to Rescue campaign?
The Ready to Rescue campaign raises awareness about opioid overdose preparedness and encourages carrying NARCAN® Nasal Spray on college campuses.
Who is involved in the Ready to Rescue campaign?
The campaign features Zac Clark, Founder and CEO of Release Recovery, and professional baseball player Davis Schneider.
Why is opioid overdose awareness important?
Opioid overdoses account for nearly 80% of drug-related deaths globally, making awareness and preparedness vital to save lives.
What does NARCAN® Nasal Spray do?
NARCAN® Nasal Spray rapidly reverses the effects of opioid overdoses when administered promptly and followed by emergency medical assistance.
How can I learn more about opioid emergency preparedness?
Visit ReadytoRescue.com for educational resources on opioid emergency preparedness and learn more about NARCAN® at its official websites.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$EBS Insider Trading Activity
$EBS insiders have traded $EBS stock on the open market 9 times in the past 6 months. Of those trades, 0 have been purchases and 9 have been sales.
Here’s a breakdown of recent trading of $EBS stock by insiders over the last 6 months:
- KATHRYN C ZOON has made 0 purchases and 2 sales selling 17,202 shares for an estimated $144,453.
- DONALD W DEGOLYER has made 0 purchases and 2 sales selling 15,481 shares for an estimated $129,993.
- KEITH KATKIN sold 15,481 shares for an estimated $128,182
- SUJATA TYAGI DAYAL has made 0 purchases and 2 sales selling 13,761 shares for an estimated $115,610.
- PAUL ANTHONY WILLIAMS (SVP, Products Business) has made 0 purchases and 2 sales selling 7,000 shares for an estimated $58,960.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.
$EBS Revenue
$EBS had revenues of $234.3M in Q2 2026. This is an increase of 66.29% from the same period in the prior year.
You can track EBS financials on Quiver Quantitative's EBS stock page.
You can access data on EBS stock through the Quiver Quantitative API.
$EBS Hedge Fund Activity
We have seen 101 institutional investors add shares of $EBS stock to their portfolio, and 99 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- SIXTH STREET PARTNERS MANAGEMENT COMPANY, L.P. added 1,200,791 shares (+inf%) to their portfolio in Q2 2026, for an estimated $10,062,628
- LSV ASSET MANAGEMENT added 799,151 shares (+89.1%) to their portfolio in Q2 2026, for an estimated $6,696,885
- PALISADE CAPITAL MANAGEMENT, LP removed 750,707 shares (-59.3%) from their portfolio in Q2 2026, for an estimated $6,290,924
- MARSHALL WACE, LLP removed 577,734 shares (-100.0%) from their portfolio in Q2 2026, for an estimated $4,841,410
- MILLENNIUM MANAGEMENT LLC added 540,184 shares (+101.5%) to their portfolio in Q2 2026, for an estimated $4,526,741
- RUSSELL INVESTMENTS GROUP, LTD. added 523,584 shares (+155.9%) to their portfolio in Q2 2026, for an estimated $4,387,633
- BLACKROCK, INC. added 375,137 shares (+8.6%) to their portfolio in Q2 2026, for an estimated $3,143,648
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
Full Release
- Ready to Rescue campaign returns to U.S. college campuses with Release Recovery Founder and CEO Zac Clark
- Partnership with professional baseball player Davis Schneider seeks to raise awareness of opioid poisoning preparedness across Canada
GAITHERSBURG, Md., Aug. 31, 2026 (GLOBE NEWSWIRE) -- In recognition of International Overdose Awareness Day (IOAD), Emergent BioSolutions (NYSE: EBS) is reaffirming its commitment to expanding awareness of opioid overdose risks and increasing preparedness to help save lives. According to the World Health Organization, opioids are associated with nearly 80 percent of drug-related deaths worldwide, highlighting the continued need for education, preparedness and access to life-saving interventions. i As opioid overdose remains a significant global public health challenge, Emergent is focused on empowering people with the information and tools needed to act in the event of an opioid overdose emergency.
“Today is a reminder of the lives lost to opioid overdoses and serves as a key moment to stand with the families, friends and communities affected by this ongoing public health crisis,” said Paul Williams, senior vice president, head of products business, global government and public affairs at Emergent BioSolutions. “While progress has been made, more work remains. By expanding access, awareness and availability to NARCAN ® Nasal Spray 4 mg and KLOXXADO ® Nasal Spray 8 mg we can help more people recognize an opioid emergency and be prepared to act when every second counts.”
As part of these efforts, Emergent’s Ready to Rescue campaign will continue its collaboration with Release Recovery and its founder and CEO, Zac Clark, by visiting college campuses across the U.S. this fall. At these events, students, faculty and staff will hear Zac’s personal story, his ongoing work with Emergent and how to use life-saving naloxone. Through these events, Ready to Rescue will raise awareness about opioid emergencies and encourage everyone to carry NARCAN ® Nasal Spray and be prepared to respond in an opioid emergency.
“As someone who has personally struggled with opioid dependency, I know that opioid overdose emergencies do not discriminate,” said Zac Clark, Founder and CEO of Release Recovery. “My own experience has fueled my passion for helping others and is one of the reasons I’m so proud of the work we do with the Ready to Rescue campaign. By continuing these conversations on college campuses, we can empower the next generation to carry NARCAN ® Nasal Spray and be prepared to help save a life.”
NARCAN ® Nasal Spray became the first U.S. FDA-approved over-the-counter (OTC) naloxone product to rapidly reverse known or suspected opioid overdoses in 2023. The same year, the U.S. saw its first of three consecutive annual declines in opioid overdose deaths, ii which experts believe is in part due to OTC naloxone access. In Canada, the opioid crisis continues to have a devastating toll, with an average of 15 lives lost each day to opioid poisonings, totaling more than 53,000 nationwide since 2016. iii To address the challenges of the Canadian crisis and break down the stigma, Emergent is continuing its partnership with professional baseball player Davis Schneider, whose involvement is deeply personal.
“My older brother Steven has inspired me to be kind to others and lead by example. As a registered nurse, brother and friend, he always showed up for others with compassion,” said Davis Schneider. “Losing him to an opioid overdose was a devastating loss for our family. That’s why I’m honored to partner with Emergent to raise awareness of opioid emergency preparedness and the importance of carrying NARCAN ® Nasal Spray. Being prepared to act in a moment of crisis can mean the difference between life and loss.”
Davis Schneider is featured on the newly released episode of Emergent’s Countermeasures podcast alongside Dr. Bonnie Milas, Clinical Professor of Anesthesiology and Critical Care Medicine at the University of Pennsylvania to help further educate the public on opioid overdose risks.
NARCAN ® Nasal Spray, when used as directed, can reverse the effects of an opioid overdose within minutes when administered promptly and followed by emergency medical assistance. By recognizing the signs of an opioid overdose, such as slowed or stopped breathing, pinpoint-sized pupils, unresponsiveness, or pale and clammy skin, and acting quickly with NARCAN ® Nasal Spray, anyone can be prepared to help save a life.
Visit ReadytoRescue.com for educational resources about opioid emergency preparedness and learn more about NARCAN ® Nasal Spray at NARCAN.com (U.S.) and NARCANNasalSpray.ca (Canada).
Zac Clark and Davis Schneider are paid spokespeople for Emergent.
About NARCAN
®
Nasal Spray
NARCAN
®
Naloxone HCl Nasal Spray 4 mg is the first FDA-approved, over-the-counter (OTC) 4 mg naloxone product for the emergency treatment of opioid overdose. NARCAN
®
Nasal Spray is not a substitute for emergency medical care. Repeat dosing may be necessary. Use as directed.
About Emergent BioSolutions
At Emergent, our mission is to protect and save lives. For over 25 years, we’ve been at work preparing those entrusted with protecting public health. We deliver protective and life-saving solutions for health threats like smallpox, mpox, botulism, Ebola, anthrax and opioid overdose emergencies. To learn more about how we help prepare communities around the world for today’s health challenges and tomorrow’s threats, visit our
website
and follow us on
LinkedIn
,
X
,
Instagram
,
Apple Podcasts
and
Spotify
.
Investor Contact:
Richard S. Lindahl
Executive Vice President, CFO
[email protected]
Media Contact:
Assal Hellmer
Vice President, Communications
[email protected]
_____________________________________________________________________
i
https://www.who.int/news-room/fact-sheets/detail/opioid-overdose/
ii
https://www.cdc.gov/nchs/pressroom/releases/20260513.html
iii
https://www.canada.ca/en/public-health/news/2025/12/statement-from-the-council-of-chief-medical-officers-of-health---latest-national-data-on-substance-related-harms.html
